Jiangsu Hansoh Pharmaceutical Co., Ltd.
134
21
27
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 134 trials
100.0%
+13.5% vs industry average
22%
30 trials in Phase 3/4
9%
2 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (134)
A Study of HS-10587 in Patients With Advanced Solid Tumors
Role: lead
MDT-bridged Radical Therapy After Aumolertinib Introduction and Followed by MRD-guided Maintained Therapy for EGFR-mutated Unresectable Stage III NSCLC (APPROACH/CTONG2101)
Role: collaborator
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
Role: lead
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
Role: lead
A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants
Role: lead
Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Role: lead
Phase 1 Study of HS-20152 in Healthy Participants
Role: lead
A Study of HS-10518 in Healthy Adult Premenopausal Females in China
Role: collaborator
A Study of HS-20136-2 in Healthy Participants
Role: lead
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
Role: lead
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Role: lead
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
Role: lead
The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
Role: collaborator
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Role: lead
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
Role: collaborator
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
Role: lead
A Phase 3 Study of HS-20094 in Patients With T2DM
Role: lead
A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer
Role: lead
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
Role: lead
A Study of HS-20094 in T2DM Participants
Role: lead